世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

炎症性腸疾患(IBD)治療薬市場予測 2018-2028年

Global Inflammatory Bowel Diseases (IBD) Drug Market Forecast 2018-2028

Aminosalicylates, Antibiotics, Corticosteroids, Immunomodulators, Biologics, Crohn’s Disease, Ulcerative Colitis

 

出版社 出版年月電子版価格 ページ数
Visiongain
ヴィジョンゲイン社
2018年5月GBP2,999
部署ライセンス
196

サマリー

The global inflammatory bowel diseases (IBD) drug market is estimated at $6.7bn in 2017 and $7.6bn in 2023. Biologic therapies held 57% share of the IBD market in 2017. The antibiotics segment of the IBD market is estimated to grow at a CAGR of 6.3% from 2018-2023.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 196-page report you will receive 141 charts– all unavailable elsewhere.

The 196-page report provides clear detailed insight into the global inflammatory bowel diseases (IBD) drug market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

• Global Inflammatory Bowel Diseases (IBD) Drug Market forecasts from 2018-2028

 Submarket forecasts from 2018-2028:
• Biologics
• Aminosalicylates
• Antibiotics
• Corticosteroids
• Immunomodulators

 

• Revenue forecast from 2018-2028 for 17 leading products:
• Humira
• Remicade
• Lialda
• Asacol
• Pentasa
• Xifaxan
• Cimzia
• Tysabri
• Simponi
• Canasa/Salofalk
• Entyvio
• Apriso
• Medrol
• Neoral
• Entocort
• Uceris
• Azulfidine

• Revenue forecasts from 2018-2028 for 11 countries:
• US
• Japan
• Germany, France, UK, Spain and Italy (EU5)
• Brazil, Russia, India and China (BRIC)

• Discussions on research and development, including drug candidates in these classes:
• Interleukin (IL) inhibitors
• Cell-adhesion molecule (CAM) inhibitors
• TNF-alpha inhibitors
• Stem cell therapies
• JAK inhibitors
• Toll-like receptor agonists

• Assessment of selected leading companies that hold major market shares in the inflammatory bowel diseases drug industry

• Discussions on trends in the industry and assesses strengths and weaknesses, as well as opportunities and threats (SWOT). It also analyses social, technological, economic and political factors (STEP) that influence the IBD market. Moreover, this report discusses factors that drive and restrain the IBD market.

Visiongain’s study is intended for anyone requiring commercial analyses for the Global Inflammatory Bowel Diseases (IBD) Drug Market. You find data, trends and predictions.

Buy our report today Global Inflammatory Bowel Diseases (IBD) Drug Market Forecast 2018-2028: Aminosalicylates, Antibiotics, Corticosteroids, Immunomodulators, Biologics, Crohn’s Disease, Ulcerative Colitis.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6



目次

Table of Contents

 

1.1 World IBD Drugs Market: Overview of Findings
1.2 Why You Should Read This Report
1.3 How the Study Delivers
1.4 Main Questions Covered in the Analysis
1.5 Who is this Report For?
1.6 Methods of Research and Analysis
1.6.1 Primary Research
1.6.2 Secondary Research
1.6.3 Market Evaluation and Forecasting Methods
1.7 Frequently Asked Questions (FAQ)
1.8 Associated Reports
1.9 About Visiongain

2. Introduction to the Inflammatory Bowel Disease Drug Market
2.1 What is Inflammatory Bowel Disease (IBD)?
2.2 Classification of IBD
2.3 Symptoms and Diagnosis of IBD
2.4 Multifactorial Causes of IBD
2.5 How Common is IBD?
2.6 What Are the Treatment Options for IBD?
2.6.1 Aminosalicylates – The Most Common Therapy
2.6.2 Antibiotics – Will There Be Any Supporting Evidence Soon?
2.6.3 Corticosteroids – Uptake from Uceris?
2.6.4 Immunomodulators – Slow to Act?
2.6.5 Monoclonal Antibodies – Not Cost-effective?
2.7 Treatment Goals for IBD – Treat-to-Target Approach?
2.8 Treatment Algorithm – is Top-Down Approach the Future Direction?

3. The World Inflammatory Bowel Disease Drug Market, 2018-2028
3.1 The Inflammatory Bowel Disease Market in 2016 and 2017
3.2 Forecast 2018-2028: Impacted by Biosimilars?
3.3 Biologic Therapies Forecast 2018-2028 – Driving the Market
3.4 Aminosalicylates Forecast 2018-2028: The steady decline
3.5 Antibiotics Forecast 2018-2028: Growing Despite Challenges
3.6 Corticosteroids Forecast 2018-2028: Driven by Uceris
3.7 Immunomodulators Forecast 2018-2028 – Will Slowly Lose Market Share

4. Market Prospects for Leading IBD Drugs, 2018-2028
4.1 Humira (AbbVie) – Growing in the First Half of Forecast Period
4.1.1 Humira: Forecast and Analysis, 2018-2028
4.2 Remicade (Janssen Biotech) – Will Slowly Be Eroded by Biosimilars
4.2.1 Remicade: Forecast and Analysis, 2018-2028
4.3 Asacol (Allergan) – Threat from Generic Competition
4.3.1 Asacol: Forecast and Analysis, 2018-2028
4.4 Pentasa (Shire) – Differentiated by Its Delivery System
4.4.1 Pentasa: Forecast and Analysis, 2018-2028
4.5 Lialda (Shire) – Will Improved Compliance Increase Revenue?
4.5.1 Lialda: Forecast and Analysis, 2018-2028
4.6 Tysabri (Perrigo) – Still Protected by Patent
4.6.1 Tysabri: Forecast and Analysis, 2018-2028
4.7 Xifaxan (Valeant) – Still Growing Significantly
4.7.1 Xifaxan: Forecast and Analysis, 2018-2028
4.8 Cimzia (UCB) – How Will It Fare Against Biosimilars?
4.8.1 Cimzia: Forecast and Analysis, 2018-2028
4.9 Entocort (AstraZeneca) – A Slow and Steady Decline?
4.9.1 Entocort: Forecast and Analysis, 2018-2028
4.10 Neoral (Novartis) – Will its Side Effect Profile Hamper Sales Growth?
4.10.1 Neoral: Forecast and Analysis, 2018-2028
4.11 Medrol (Pfizer) – Another Leading Steroid
4.11.1 Medrol: Forecast and Analysis, 2018-2028
4.12 Canasa (Allergan) – Will a Generic Competitor Soon Be Available?
4.12.1 Canasa/Salofalk: Forecast and Analysis, 2017-2027
4.13 Apriso (Valeant) – Challenger to Asacol?
4.13.1 Apriso: Forecast and Analysis, 2018-2028
4.14 Azulfidine (Pfizer) – Tried, Tested and Staying in the Market
4.14.1 Azulfidine: Forecast and Analysis, 2018-2028
4.15 Entyvio (Takeda Pharmaceuticals) – Driving the Biologics Segment
4.15.1 Entyvio: Forecast and Analysis, 2018-2028
4.16 Simponi (Janssen Biotech) – Rising Star for the Market?
4.16.1 Simponi: Forecast and Analysis, 2018-2028
4.17 Uceris (Valeant) – Meeting Patients’ Needs with Its Delivery System
4.17.1 Uceris: Forecast and Analysis, 2018-2028

5. Leading National Markets: Sales Outlooks, 2017-2027
5.1 IBD Drugs - Leading National Markets 2017
5.2 The US IBD Drug Market, 2018-2028 – The World Leader
5.3 The Japanese IBD Drug Market, 2018-2028 – Growing Significantly?
5.4 The EU-5 IBD Drug Market, 2018-2028 – Driven by the UK
5.4.1 The German IBD Drug Market, 2018-2028
5.4.2 The French IBD Drug Market, 2018-2028
5.4.3 The UK IBD Drug Market, 2017-2027
5.4.4 The Spanish IBD Drug Market, 2017-2027
5.4.5 The Italian IBD Drug Market, 2018-2028
5.5 IBD Drug Markets in BRIC Countries – Taking More Market Share
5.5.1 The Brazilian IBD Drug Market, 2018-2028
5.5.2 The Russian IBD Drug Market, 2018-2028
5.5.3 The Indian Drug Market, 2018-2028
5.5.4 The Chinese IBD Drug Market, 2018-2028

6. The R&D Pipeline for Inflammatory Bowel Disease, 2017
6.1 Top Marketed and pipeline products – Launch dates and Patent expiry
6.2 Interleukin (IL) Inhibitors – One of the Main Areas of Innovation
6.2.1 CyCol (Sigmoid Pharma)
6.2.2 PF-04236921 (Pfizer)
6.2.3 QAX 576 (Novartis)
6.2.4 TNF Kinoid (Neovacs)
6.2.5 Vidofludimus (4SC) – Suspended
6.2.6 Stelara (Ustekinumab, CNTO 1275, Janssen Biotech)
6.3 Cell-Adhesion Molecule (CAM) Inhibitors – A Promising Avenue
6.3.1 AJG 511 (Ajinomoto Pharmaceutical Co.)
6.3.2 AJM 300 (Ajinomoto Pharmaceuticals)
6.3.3 MEDI 7183/AMG 181 (AstraZeneca)
6.3.4 Etrolizumab (Roche)
6.3.5 PF-00547659 (Pfizer)
6.3.6 Alicaforsen (ISIS 2302, Atlantic Healthcare)
6.3.7 MEDI-2070/AMG 139 (AstraZeneca & Amgen)
6.4 TNF-α Inhibitors – a Specific Target
6.4.1 AVX-470 (Avaxia Biologics)
6.4.2 Ozoralizumab (ALX-0061, Ablynx)
6.5 Stem Cell Therapies – Basis for a Cure?
6.5.1 Ovasave (TxCell)
6.5.2 MultiStem (Athersys and Pfizer)
6.5.3 Prochymal (Remestemcel-L, Osiris Therapeutics)
6.5.4 Cx601 (TiGenix)
6.6 JAK Inhibitors – New Target Pathway
6.6.1 JNJ-54781532 (Janssen)
6.6.2 Xeljanz, (Tofacitinib, CP-690550, Pfizer)
6.7 Toll-like Receptor Agonists
6.7.1 BL-7040 (BioLineRX)
6.7.2 Kappaproct (InDex Pharmaceuticals)
6.8 Other Classes of Agent
6.8.1 Trichuris suis ova (CNDO-201, Coronado Biosciences)
6.8.2 GLPG0974 (Galapagos)
6.8.3 RPC1063 (Receptos/now Celgene)
6.8.4 SGX203 (Soligenix)
6.8.5 Mongersen (GED-0301, Celgene)
6.8.6 Tetomilast (OPC-6535, Otsuka)
6.8.7 Laquinimod (Active Biotech)
6.8.8 RHB-104 (RedHill Biopharma)
6.8.9 Ozanimod (Celgene)
6.8.10 GED-0301 (Celgene)
6.9 Biosimilar Candidates – Promising Competitors of Leading Biologics
6.9.1 Adalimumab Biosimilars
6.9.2 Infliximab Biosimilars

7. Qualitative Analysis of the Inflammatory Bowel Disease Drug Industry and Market, 2017
7.1 SWOT and STEP Analysis of the IBD Drugs Market
7.2 What Factors Will Stimulate the IBD Market?
7.2.1 Increasing Disease Incidence in Most National Markets
7.2.2 Better Diagnosis – Early Referrals
7.2.3 Delivery Systems Improve Existing Drugs
7.2.4 Biological Drugs – Driving the Market Significantly
7.2.5 Socioeconomic Costs of IBD
7.3 What Factors Will Restrain the Market?
7.3.1 Lack of Understanding of Disease Aetiology
7.3.2 Compliance – Frequent Dosing is Inconvenient
7.3.3 Limitations of Biologics – Side Effect Profiles
7.3.4 The Possible Development of Alternative Treatments
7.3.5 Surgery – Treatment for Recalcitrant IBD
7.3.6 Health Care Cost Containment

8. Leading Companies in the IBD Pharmaceuticals Market, 2017
8.1 The Largest Companies by Revenue
8.1.1 AbbVie
8.1.2 Janssen Biotech
8.1.3 Allergan
8.1.4 Shire Pharmaceuticals
8.1.5 Takeda Pharmaceuticals

9. Conclusions of the Study
9.1 The IBD Drugs Market Will Expand from 2018 to 2028
9.2 Aminosalicylates and Other Non-Biologic Treatments
9.3 Biological Treatments Dominate the Market
9.4 Improvements Needed in IBD Therapy
9.5 Future IBD Treatments: R&D Efforts Look Promising
9.6 The IBD Sector: Looking to the Future with Confidence

Appendices
Associated Visiongain Reports
Visiongain Report Sales Order Form
About Visiongain
Visiongain Report Evaluation Form

List of Tables
Table 2.1 Differentiating Crohn’s Disease and Ulcerative Colitis
Table 2.2 Worldwide Prevalence Rates for IBD, 2016
Table 2.3 Worldwide Incidence Rates for IBD, 2016
Table 2.4 Geographical Variations in the Incidence of IBD, 2016
Table 2.5 Other Drug Types Used to Treat IBD, 2016
Table 2.6 Treatment Protocol for IBD, 2016
Table 3.1 Global IBD Drug Sales ($m), Annual Growth Rates (%) and Market Shares (%) by Segment, 2016 and 2017
Table 3.2 Global IBD Drug Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2018-2028
Table 3.3 Global IBD Drug Forecast by Drug Category: Revenues ($m), AGR (%), CAGR (%), 2018-2028
Table 3.4 Global IBD Drug Market Drivers and Restraints 2018-2028
Table 3.5 Global Biologics Forecast for IBD Market: Revenues ($m), AGR (%), CAGR (%), 2018-2028
Table 3.6 Global Biologic Therapies Drivers and Restraints, 2018-2028
Table 3.7 Global Aminosalicylates Forecast for IBD Market: Revenues ($m), AGR (%), CAGR (%), 2018-2028
Table 3.8 Global Aminosalicylates Drivers and Restraints, 2018-2028
Table 3.9 Global Antibiotics Forecast for IBD Market: Revenues ($m), AGR (%), CAGR (%), 2018-2028
Table 3.10 Global Antibiotics Drivers and Restraints, 2018-2028
Table 3.11 Global Corticosteroids Forecast for IBD Market: Revenues ($m), AGR (%), CAGR (%), 2018-2028
Table 3.12 Global Corticosteroids Drivers and Restraints, 2018-2028
Table 3.13 Global Immunomodulators Forecast for IBD Market: Revenues ($m), AGR (%), CAGR (%), 2018-2028
Table 3.14 Global Immunomodulators Drivers and Restraints, 2018-2028
Table 4.1 Leading IBD Treatments by Revenue ($m), 2017
Table 4.2 Leading IBD Medicines: Revenue Forecasts ($m), AGR (%), 2018-2028
Table 4.3 World Humira Revenue Forecast: Revenues ($m), AGR (%), CAGR (%), 2018-2028
Table 4.4 Drivers and Restraints for Humira, 2018-2028
Table 4.5 World Remicade Forecast: Revenues ($m), AGR (%), CAGR (%), 2018-2028
Table 4.6 Drivers and Restraints for Remicade, 2018-2028
Table 4.7 World Asacol Forecast: Revenues ($m), AGR (%), CAGR (%), 2018-2028
Table 4.8 Drivers and Restraints for Asacol, 2018-2028
Table 4.9 World Pentasa Forecast: Revenues ($m), AGR (%), CAGR (%), 2018-2028
Table 4.10 Drivers and Restraints for Pentasa, 2018-2028
Table 4.11 World Lialda Forecast: Revenues ($m), AGR (%), CAGR (%), 2018-2028
Table 4.12 Drivers and Restraints for Lialda, 2018-2028
Table 4.13 World Tysabri Forecast: Revenues ($m), AGR (%), CAGR (%), 2018-2028
Table 4.14 Drivers and Restraints for Tysabri, 2018-2028
Table 4.15 World Xifaxan Forecast: Revenues ($m), AGR (%), CAGR (%), 2018-2028
Table 4.16 Drivers and Restraints for Xifaxan, 2018-2028
Table 4.17 World Cimzia Forecast: Revenues ($m), AGR (%), CAGR (%), 2018-2028
Table 4.18 Drivers and Restraints for Cimzia, 2018-2028
Table 4.19 World Entocort Forecast: Revenues ($m), AGR (%), CAGR (%), 2018-2028
Table 4.20 Drivers and Restraints for Entocort, 2018-2028
Table 4.21 World Neoral Forecast: Revenues ($m), AGR (%), CAGR (%), 2018-2028
Table 4.22 Drivers and Restraints for Neoral, 2018-2028
Table 4.23 World Medrol Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027
Table 4.24 Drivers and Restraints for Medrol, 2018-2028
Table 4.25 World Canasa Forecast: Revenues ($m), AGR (%), CAGR (%), 2018-2028
Table 4.26 Drivers and Restraints for Canasa, 2018-2028
Table 4.27 World Apriso Forecast: Revenues ($m), AGR (%), CAGR (%), 2018-2028
Table 4.28 Drivers and Restraints for Apriso, 2018-2028
Table 4.29 World Azulfidine Forecast: Revenues ($m), AGR (%), CAGR (%), 2018-2028
Table 4.30 Drivers and Restraints for Azulfidine, 2018-2028
Table 4.31 World Entyvio Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027
Table 4.32 Drivers and Restraints for Entyvio, 2018-2028
Table 4.33 World Simponi Forecast: Revenues ($m), AGR (%), CAGR (%), 2018-2028
Table 4.34 Drivers and Restraints for Simponi, 2018-2028
Table 4.35 World Uceris Forecast: Revenues ($m), AGR (%), CAGR (%), 2018-2028
Table 4.36 Drivers and Restraints for Uceris, 2018-2028
Table 5.1 IBD Drug Revenues ($m) by Leading Country, 2017
Table 5.2 US IBD Drug Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2018-2028
Table 5.3 Japanese IBD Drug Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027
Table 5.4 EU5 IBD Drug Market Forecasts: Revenues ($m), AGR (%), CAGR (%), 2018-2023
Table 5.5 EU5 IBD Drug Market Forecasts: Revenues ($m), AGR (%), CAGR (%), 2023-2028
Table 5.6 German IBD Drug Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2018-2028
Table 5.7 French IBD Drug Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027
Table 5.8 UK IBD Drug Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027
Table 5.9 Spanish IBD Drug Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2018-2028
Table 5.10 Italian IBD Drug Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027
Table 5.11 BRIC IBD Drug Market Forecasts: Revenues ($m), AGR (%), CAGR (%), 2018-2023
Table 5.12 BRIC IBD Drug Market Forecasts: Revenues ($m), AGR (%), CAGR (%), 2023-2027
Table 5.13 Brazilian IBD Drug Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2018-2028
Table 5.14 Russian IBD Drug Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2018-2028
Table 5.15 Indian IBD Drug Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027
Table 5.16 Chinese IBD Drug Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2018-2028
Table 6.1 Key Patent dates for marketed and pipeline products
Table 6.2 Selected IL Inhibitors in Clinical Development, 2018
Table 6.3 Selected CAM Inhibitors in Clinical Development, 2018
Table 6.4 Selected TNF-α Inhibitors in Clinical Development, 2018
Table 6.5 Selected Stem Cell Therapies in Clinical Development, 2018
Table 6.6 Selected JAK Inhibitors in Clinical Development, 2018
Table 6.7 Selected Toll-like Receptor Agonist in Clinical Development, 2018
Table 6.8 Selected Other Classes in Clinical Development, 2018
Table 7.1 Strengths, Weaknesses, Opportunities and Threats in the IBD Drug Market
Table 7.2 Social, Technological, Economic and Political Forces on the IBD Drug Market
Table 8.1 AbbVie Revenues ($m) and Market Share (%), 2017
Table 8.2 Janssen Biotech Revenues ($m) and Market Share (%), 2017
Table 8.3 Allergan Revenues ($m) and Market Share (%), 2017
Table 8.4 Shire Revenues ($m) and Market Share (%), 2017
Table 8.5 Takeda Revenues ($m) and Market Share (%), 2017
Table 9.1 Global IBD Revenue Forecasts ($m), Market Share (%) by Product Category, 2018, 2023, 2028
Table 9.2 Global IBD Revenue Forecasts ($m), CAGR (%) and Market Shares (%) by Region, 2018, 2023, 2028
Table 9.3 Summary of IBD Market Drivers and Restraints, 2018-2028

List of Figures
Figure 1.1 Inflammatory Bowel Disease Market Segmentation, 2017
Figure 3.1 World IBD Drugs Market Shares by Product Type (%), 2018
Figure 3.2 Global IBD Drug Market Forecast ($m), 2018-2028
Figure 3.3 World IBD Drugs Market Shares by Product Type (%), 2028
Figure 3.4 Global Biologics Forecast for IBD Market ($m), 2018-2028
Figure 3.5 Global Aminosalicylates Forecast for IBD Market ($m), 2018-2028
Figure 3.6 Global Antibiotics Forecast for IBD Market ($m), 2018-2028
Figure 3.7 Global Corticosteroids Forecast for IBD Market ($m), 2018-2028
Figure 3.8 Global Immunomodulators Forecast for IBD Market ($m), 2018-2028
Figure 4.1 World Humira Revenue Forecast ($m), 2018-2028
Figure 4.2 World Remicade Forecast ($m), 2018-2028
Figure 4.3 World Asacol Forecast ($m), 2018-2028
Figure 4.4 World Pentasa Forecast ($m), 2018-2028
Figure 4.5 World Lialda Forecast ($m), 2018-2028
Figure 4.6 World Tysabri Forecast ($m), 2018-2028
Figure 4.7 World Xifaxan Forecast ($m), 2018-2028
Figure 4.8 World Cimzia Forecast ($m), 2018-2028
Figure 4.9 World Entocort Forecast ($m), 2018-2028
Figure 4.10 World Neoral Forecast ($m), 2018-2028
Figure 4.11 World Medrol Forecast ($m), 2018-2028
Figure 4.12 World Canasa Forecast ($m), 2018-2028
Figure 4.13 World Apriso Forecast ($m), 2018-2028
Figure 4.14 World Azulfidine Forecast ($m), 2018-2028
Figure 4.15 World Entyvio Forecast ($m), 2018-2028
Figure 4.16 World Simponi Forecast ($m), 2018-2028
Figure 4.17 World Uceris Forecast ($m), 2018-2028
Figure 5.1 Global IBD Drug Market by Leading Country (%), 2018
Figure 5.2 Global IBD Drug Market by Leading Country (%), 2028
Figure 5.3 US IBD Drug Market Forecast ($m), 2018-2028
Figure 5.4 Japanese IBD Drug Market Forecast ($m), 2018-2028
Figure 5.5 EU5 IBD Drug Market Forecasts ($m), 2018-2028
Figure 5.6 German IBD Drug Market Forecast ($m), 2018-2028
Figure 5.7 French IBD Drug Market Forecast ($m), 2018-2028
Figure 5.8 UK IBD Drug Market Forecast ($m), 2018-2028
Figure 5.9 Spanish IBD Drug Market Forecast ($m), 2018-2028
Figure 5.10 Italian IBD Drug Market Forecast ($m), 2018-2028
Figure 5.11 BRIC IBD Drug Market Forecasts ($m), 2018-2028
Figure 5.12 Brazilian IBD Drug Market Forecast ($m), 2018-2028
Figure 5.13 Russian IBD Drug Market Forecast ($m), 2018-2028
Figure 5.14 Indian IBD Drug Market Forecast ($m), 2018-2028
Figure 5.15 Chinese IBD Drug Market Forecast ($m), 2018-2028
Figure 8.1 AbbVie Assets – Marketed and Pipeline 2016
Figure 8.2 AbbVie Deals and Partnerships 2011 - 2016
Figure 8.3 Janssen Assets – Marketed and Pipeline 2016
Figure 8.4 Janssen – Deals and Partnerships 2011 - 2016
Figure 8.5 Allergan Assets – Marketed and Pipeline 2016
Figure 8.6 Allergan – Deals and Partnerships 2011 - 2016
Figure 8.7 Shire Assets – Marketed and Pipeline 2016
Figure 8.8 Shire – Deals and Partnerships 2011 - 2016
Figure 8.9 Takeda Assets – Marketed and Pipeline 2016
Figure 8.10 Shire – Deals and Partnerships 2011 - 2015

 

4SC
Abbott Laboratories
AbbVie
Ablynx
Actavis
Active Biotech
Ajinomoto
Alfasigma Group
Allergan
Almirall
Amgen
Aptalis Pharmaceuticals
Astellas
AstraZeneca
Athersys
Atlantic Healthcare
Avaxia Biologics
BioLineRx
Biosafe
Boehringer Ingelheim
Calico
Celgene
Celltrion
Centocor Ortho Biotech
Cipla
Coherus Biosciences
Coronado Biosciences
Cosmo Pharmaceuticals
Dr. Falk Pharma
Eddingpharm
Elan Pharmaceuticals
Epirus Biopharmaceuticals
Ferring
Forest Laboratories
Galapagos
Giaconda
Google
Harbor Biosciences
Hospira
Immunic
InDex Pharmaceuticals
Infinity Pharmaceuticals
Isis Pharmaceuticals
Janssen Biotech
Johnson & Johnson
Kissei Pharmaceutical Co., Ltd
LG Sciences
Lupin
MedImmune
Mochida
Mutare Health
Mylan Pharmaceuticals
Neovacs
Nisshin Kyorin
Nogra Pharma
NovaMedica
Novartis
Oncobiologics
Ortho Biotech
Osiris Therapeutics
Otsuka
Ovamed
Palau Pharma
Par Pharmaceuticals
Pendopharm
Perrigo
Pfenex
Pfizer
Pharmascience
Pluristem Therapeutics
Qu Biologics
Quest Diagnostics
Ranbaxy Laboratories
Receptos
RedHill Biopharma
Reliance Life Sciences
Roche
Salix Pharmaceuticals
Sandoz
Sanofi
Santarus
Sequella
Shire Pharmaceuticals
Sigmoid Pharma
Soligenix
SonarMD
Takeda Pharmaceuticals
Teva Pharmaceutical Industries
TiGenix
Toray Industries
Torrent Pharmaceuticals Ltd.
TxCell
UCB
Valeant
Warner Chilcott
Zeria Pharmaceutical
Zydus Cadila

List of Organisations Mentioned in the Report
American Gastroenterological Association (AGA)
Case Western Reserve University
Center for Human Disease Research, Leiden
Centrale Commissie Mensgebonden Onderzoek (CCMO)
Centres for Disease Control and Prevention (US)
Crohn’s and Colitis Foundation of Canada
European Commission
European Crohn’s and Colitis Organisation (ECCO)
European Medicines Agency (EMA)
Food and Drug Administration (US FDA)
Georgia State University
German Society of Gastroenterology (DGVS)
Hebrew University of Jerusalem
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
Institut National de la Santé et de la Recherche Médicale (INSERM)
Karolinska Institute
National Health Service (UK NHS)
National Institute for Health and Care Excellence (UK NICE)
National Institutes of Health (US NIH)
Servicio Sanitario Nazionale (SSN, Italy)
The Crohn’s and Colitis UK Foundation
The European Federation of Crohn's and Ulcerative Colitis Associations
The Scripps Research Institute (TSRI)
The University of Iowa

 

ページTOPに戻る

あなたが最近チェックしたレポート一覧

  • 最近チェックしたレポートはありません。

お問合は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのお問合せはこちらのフォームから承ります

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

<無料>メルマガに登録する

 

 

ページTOPに戻る